MBL2 Protein
-
- Target See all MBL2 Proteins
- MBL2 (Mannose-Binding Lectin (Protein C) 2, Soluble (MBL2))
- Protein Type
- Recombinant
-
Origin
- Mouse
-
Source
- Human Cells
- Purpose
- Recombinant Mouse MBL2/MBP-C Protein
- Sequence
- Glu19-Asp244
- Characteristics
- Recombinant Mouse Mannose Binding Lectin 2 is produced by our Mammalian expression system and the target gene encoding Glu19-Asp244 is expressed.
- Purity
- > 95 % as determined by SDS-PAGE
- Endotoxin Level
- < 1.0 EU per μg as determined by the LAL method.
-
-
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Please refer to the printed manual for detailed information.
- Buffer
- Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.
- Storage
- 4 °C,-20 °C,-80 °C
- Storage Comment
- Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
-
- Target
- MBL2 (Mannose-Binding Lectin (Protein C) 2, Soluble (MBL2))
- Alternative Name
- MBL2/MBP-C (MBL2 Products)
- Background
-
Background: Mannose-binding Lectin (MBL) is an acute phase protein bearing to the family of collectins produced by the liver as a monomer that forms a triple helix. Once released in serum, it further polymerizes forming dimers to octamers. The degree of serum polymerization is critical for the biological activity of MBL. MBL has higher affinity to microbial polysaccharides or their glycoconjugates. MBL was shown earlier to bind cell surfaces of bacteria, fungi, protozoa and viruses and acts as an acute-phase plasma protein (APP) during infection and inflammation. MBL activates the lectin-complement pathway, promotes opsonophagocytosis and modulates inflammation.
Synonym: Mannose binding lectin (C), isoform CRA_b, Mannose-binding protein C, Mbl2, MBL-2, Mannose Binding Lectin 2
- Molecular Weight
- 24.0 kDa
- UniProt
- Q3UEK1
- Pathways
- Complement System, Positive Regulation of Immune Effector Process
-